Prolium Bioscience

Private

Clinical-stage biotech developing PRO-203, a potential best-in-class CD20xCD3 T-cell engager for severe autoimmune diseases including systemic sclerosis and lupus.

Founders Scott Requadt

CEO Scott Requadt

Company

Founded

2025

Headquarters

New York, New York, United States

Employees

11-50

Financials

Total Funding

$50M

Revenue (ARR)

pre-revenue

Sectors

Healthtech Biotech

www.proliumbio.com

Funding History

1 round

Series A Mar 3, 2026

$50M

RTW Investments (Lead)

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.